Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents

GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00156143

Acronym

TAUBER

Enrollment

Registered

2005-09-12

Start date

2002-04-30

Completion date

2005-04-30

Last updated

2007-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency

Brief summary

To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.

Interventions

PROCEDUREBlood sample

PROCEDURERadiography

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 20 Years

Healthy volunteers

Inclusion criteria

* Males or females : Chronological age \> or = 15 years and \< or = 20 years for females * Chronological age \> or = 17 years and \< or = 20 years for males * GHD of childhood onset treated for at least 2 years * Last GH injection at least 12 months before baseline visit

Exclusion criteria

* Turner's syndrome * Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT \> 2 X ULN

Design outcomes

Primary

Measure	Time frame
Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026